Physician profile
Jenny Dang
NPI 1457197295
$2,252.78
in general payments reported to CMS, 2019-2025
12 companies · $1,483 in 2025
The $1,483 reported for 2025 was more than what 95% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $770 · 2025: $1,483.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,728 · Consulting Fee: $350 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,727.78 |
| Consulting Fee | $350.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $175.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $693.40 | 2024-2025 | Hydrus Microstent, Air Optix, Voyager Dslt |
| Bausch & Lomb Americas INC. | $481.23 | 2024-2025 | Infuse, Miebo, Xiidra |
| Coopervision INC. | $233.38 | 2024-2025 | Clariti Contact Lens, Myday Contact Lens, Misight Contact Lens |
| Johnson & Johnson Vision Care, INC. | $210.30 | 2025 | Acuvue |
| Dompe US, INC. | $152.28 | 2024-2025 | Oxervate |
| Apellis Pharmaceuticals, INC. | $125.00 | 2024 | Syfovre |
| Astellas Pharma US INC | $120.26 | 2025 | Izervay |
| Abbvie INC. | $118.99 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $54.78 | 2025 | |
| Tarsus Pharmaceuticals, INC. | $28.84 | 2025 | Xdemvy |
| Harrow Eye, LLC | $18.47 | 2025 | Vevye |
| Ani Pharmaceuticals, INC. | $15.85 | 2024 | Purified Cortrophin Gel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jenny Dang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.